GW Pharmaceuticals PLC- (NASDAQ:GWPH) shares gapped up prior to trading on Thursday . The stock had previously closed at $93.88, but opened at $93.94. GW Pharmaceuticals PLC- shares last traded at $95.48, with a volume of 277,847 shares.

Several research analysts have commented on the company. Leerink Swann restated a “buy” rating and issued a $130.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, June 21st. Vetr downgraded GW Pharmaceuticals PLC- from a “buy” rating to a “hold” rating and set a $87.65 target price for the company. in a research note on Wednesday, April 20th. Cantor Fitzgerald assumed coverage on GW Pharmaceuticals PLC- in a research note on Thursday, June 2nd. They issued a “buy” rating and a $181.00 target price for the company. Piper Jaffray Cos. restated a “buy” rating and issued a $147.00 target price on shares of GW Pharmaceuticals PLC- in a research note on Sunday, June 26th. Finally, Goldman Sachs Group Inc. dropped their price target on GW Pharmaceuticals PLC- from $135.00 to $105.00 in a research report on Tuesday, June 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $127.47.

The firm’s 50-day moving average price is $90.85 and its 200 day moving average price is $72.40. The stock’s market cap is $2.07 billion.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last issued its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($1.57) by $1.48. The business earned $3.81 million during the quarter, compared to analysts’ expectations of $5.99 million. During the same quarter in the previous year, the company posted ($0.03) earnings per share. The company’s quarterly revenue was down 58.3% compared to the same quarter last year. Equities analysts anticipate that GW Pharmaceuticals PLC- will post ($4.19) earnings per share for the current year.

A hedge fund recently raised its stake in GW Pharmaceuticals PLC- stock. Trexquant Investment LP raised its stake in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 188.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 23,719 shares of the biopharmaceutical company’s stock after buying an additional 15,509 shares during the period. Trexquant Investment LP owned approximately 0.11% of GW Pharmaceuticals PLC- worth $1,647,000 at the end of the most recent reporting period.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.